OncoC4

aid: oncoc4
name: OncoC4
description: OncoC4, Inc. is a privately held, late clinical-stage biopharmaceutical company headquartered in Rockville, Maryland,
  founded in 2020, with subsidiaries in Nanjing, Guangzhou and Beijing, China, and Brisbane, Australia. The company discovers
  and develops novel biologics for the treatment of cancer, working across immune checkpoints including CTLA-4, CD24, PD-1/VEGF
  and the Siglec family, with monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and CAR T-cell therapies.
  Its lead clinical candidate is gotistobart (BNT316/ONC-392), a next-generation anti-CTLA-4 antibody co-developed and commercialized
  with BioNTech under a strategic collaboration announced in March 2023. OncoC4 publishes no developer program, public API,
  SDK or developer documentation; its corporate website runs on the Umbraco CMS, which serves a default OpenID Connect / OAuth
  2.0 discovery document and JWKS for CMS member authentication.
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  probe_state: none
  source:
  - authentication
  - scopes
  - security
  generated: '2026-11-06'
  method: derived
image: https://oncoc4.com/media/tlofbavh/logo.svg
url: https://raw.githubusercontent.com/api-evangelist/oncoc4/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Life Sciences
- Oncology
- Immunotherapy
- Clinical Trials
- Healthcare
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/oncoc4-domain-security.yml
- type: WellKnown
  url: well-known/oncoc4-well-known.yml
- type: Authentication
  url: authentication/oncoc4-authentication.yml
- type: OAuthScopes
  url: scopes/oncoc4-scopes.yml
- type: Conformance
  url: conformance/oncoc4-conformance.yml
- type: LLMsTxt
  url: llms/oncoc4-llms.txt
- type: Website
  url: https://oncoc4.com/en/
- type: About
  url: https://oncoc4.com/en/about-us/
- type: Contact
  url: https://oncoc4.com/en/contact/
- type: PrivacyPolicy
  url: https://oncoc4.com/en/privacy-policy/
- type: Careers
  url: https://oncoc4.com/en/careers/
- type: News
  url: https://oncoc4.com/en/news-resources/news/
- type: LinkedIn
  url: https://www.linkedin.com/company/oncoc4
- type: SecondaryMarket
  url: https://forgeglobal.com/oncoc4_stock/
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 9
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: OncoC4 is a late clinical-stage biopharmaceutical company whose product is a drug, not software — the entire oncoc4.com
    site is an Umbraco-hosted corporate brochure (about, pipeline, clinical trials, publications, careers) with no developer
    section, and the only machine-readable documents it serves are Umbraco's default OIDC/OAuth member-login discovery files.
  evidence:
  - url: https://oncoc4.com/openapi.json
    status: 404
  - url: https://oncoc4.com/api-docs
    status: 404
  - url: https://oncoc4.com/graphql
    status: 404
  - url: https://oncoc4.com/.well-known/agent-card.json
    status: 404
  - url: https://oncoc4.com/.well-known/openid-configuration
    status: 200
  checked: '2026-08-04'